AMSilk, headquartered in Munich, Germany, plans to scale-up production capacity for its bio-based silk materials by several thousand tons a year and expand its production network outside Europe.

The company’s scalable biotechnological platform and patent portfolio enable it to produce large quantities of premium bio-fabricated silk materials, including high-performance Biosteel fibres for textiles, at constant quality.

The company has also announced that co-founder and CTO Dr. Lin Römer has stepped down from the management team and will move to a part-time consultancy role supporting AMSilk with his broad and versatile expertise and know-how. Over the past decade, he has been instrumental in bringing the company’s biotech products from the lab to industrial scale, resulting in the successful market launch of the world’s first artificial spider silk products.

“As AMSilk enters a new phase of growth, we are accelerating our plans for the industrial scale up of production of our materials,” said Wolfgang Colberg, chair of the advisory board. “I would like to thank Lin for his outstanding work over many years. His achievements for AMSilk, which he co-founded and shaped from day one, cannot be overstated.”

In May 2022, Klaus Kjeldal was appointed chief production officer and managing director to lead the scale-up of AMSilk’s protein production.

AMSilk offers its range for industrial applications worldwide and has announced collaborations and partnerships with world leading brands like Adidas and Airbus. The organic high-performance materials can be used in multiple ways and are suitable for medical devices as well as for personal care products.

www.amsilk.com